Prodromal Alzheimer's Disease Presenting as Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Amyloid-Related Imaging Abnormalities and High Cerebrospinal Fluid Anti-Aβ Autoantibodies

Journal of Alzheimer's Disease

Volumn 45, Issue 2, 2015, Pages 363-367

  Boncoraglio, Giorgio B ^a   Piazza, Fabrizio ^b,c   Savoiardo, Mario ^a   Farina, Laura ^a   Difrancesco, Jacopo C ^a,b   Prioni, Sara ^a   Tagliavini, Fabrizio ^a   Parati, Eugenio A ^a   Giaccone, Giorgio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's Disease Biomarkers International (iCAB) Network Coordinator   (Italy)

Author keywords

Alzheimer's disease; amyloid related imaging abnormalities; anti A autoantibodies; cerebral amyloid angiopathy; cerebral amyloid angiopathy related inflammation; subarachnoid hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AUTOANTIBODY; ENOXAPARIN; METHYLPREDNISOLONE; PREDNISONE; AMYLOID;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; APRAXIA; ARM WEAKNESS; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ATROPHY; BRAIN BIOPSY; BRAIN CORTEX; CARCINOMATOUS MENINGITIS; CARDIOEMBOLIC STROKE; CASE REPORT; CEREBRAL AMYLOID ANGIOPATHY RELATED INFLAMMATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DEMENTIA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FATIGUE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEURITE; NEUROIMAGING; NEUROPIL THREAD; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROTEIN CEREBROSPINAL FLUID LEVEL; RARE DISEASE; SENILE PLAQUE; SUBARACHNOID HEMORRHAGE; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; VASCULAR AMYLOIDOSIS; VASCULAR NECROSIS; COMPLICATION; IMMUNOLOGY; METABOLISM;

AGED; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AUTOANTIBODIES; CEREBRAL AMYLOID ANGIOPATHY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84925347817     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142376     Document Type: Article

References (20)

1. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial, Investigators (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
2. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11, 241-249.
3. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370, 322-333.
4. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
5. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69, 198-207.
6. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, RichterRW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM (2012) Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69, 1430-1440.
7. DiFrancesco JC, Brioschi M, Brighina L, Ruffmann C, Saracchi E, Costantino G, Galimberti G, Conti E, Curtò NA, Marzorati L, Remida P, Tagliavini F, Savoiardo M, Ferrarese C (2011) Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation:Acase report. Neurology 76, 842-844.
8. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G, Colombo A, Lanzani F, Piscosquito G, Carriero MR, Giaccone G, Tagliavini F, Ferrarese C, DiFrancesco JC (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloidmodifying therapies. Ann Neurol 73, 449-458.
9. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, Greenberg SM (2007) Course of cerebral amyloid angiopathy-related inflammation. Neurology 68, 1411-1416.
10. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM (2004) Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 55, 250-256.
11. Cordonnier C, van der Flier WM (2011) Brain microbleeds and Alzheimer's disease: Innocent observation or key player?Brain 134(Pt 2), 335-344.
12. Bulbarelli A, Lonati E, Brambilla A, Orlando A, Cazzaniga E, Piazza F, Ferrarese C, Masserini M, SanciniG(2012) Abeta42 production in brain capillary endothelial cells after oxygen and glucose deprivation. Mol Cell Neurosci 49, 415-422.
13. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7, 396-401.
14. Greenberg SM, Frosch MP (2011) Life imitates art: Antiamyloid antibodies and inflammatory cerebral amyloid angiopathy. Neurology 76, 772-773.
15. Werring DJ, Sperling R (2013) Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: Variations on the same ARIA? Ann Neurol 73, 439-441.
16. Machida K, Tsuchiya-Suzuki A, Sano K, Arima K, Saito Y, Kametani F, Ikeda S (2012) Postmortem findings in a patient with cerebral amyloid angiopathy actively treated with corticosteroid. Amyloid 19, 47-52.
17. Sakaguchi H, Ueda A, Kosaka T, Yamashita S, Kimura E, Yamashita T, Maeda Y, Hirano T, Uchino M (2011) Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: Case report and review of the literature. J Neuroinflammation 8, 116.
18. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
19. Monsell SE, Mock C, Roe CM, Ghoshal N, Morris JC, Cairns NJ, KukullW(2013) Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology 80, 2121-2129.
20. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentation of Alzheimer's disease. Brain 130, 2636-2645.